Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118484 | 0.86 | MAPT (0.40) | KMT2AMAPTTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL6678378 | 0.83 | PKM (0.50) | PKMKMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL6682663 | 0.83 | PKM (0.47) | PKMKMT2AMAPTLMNATP53 | |
| SCHEMBL7061142 | 0.80 | SMN1; SMN2 (0.43) | PKMKMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL7115636 | 0.74 | KMT2A (0.49) | PKMKMT2AMAPTLMNATP53 | |
| SCHEMBL7120798 | 0.74 | MAPT (0.49) | MAPTLMNATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL6684431 | 0.72 | KMT2A (0.49) | PKMKMT2AMAPTLMNATP53 | |
| SCHEMBL6678882 | 0.71 | ALDH1A1 (0.43) | KMT2AMAPTTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL6684343 | 0.70 | MAPT (0.41) | KMT2AMAPTTP53ALDH1A1TSHR | |
| SCHEMBL13746192 | 0.70 | PKM (0.76) | PKMKMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | PKM 2081/4885KMT2A 3799/4885MAPT 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.